Quick Takeaways
- BCAX - Bicara Therapeutics Inc. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: +$31,312,648.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 19 Insiders of Bicara Therapeutics Inc.
- Symbol
- BCAX on Nasdaq
- Location
- Boston, MA
What Changed
- Buy value: $39,999,780; sell value: $8,687,131.
- Net share flow: +2,012,035.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$31,312,648.
Buys
$39,999,780
Shares: 2,500,000
Insiders: 1
Sells
$8,687,132
Shares: 487,965
Insiders: 5
Net
+$31,312,648
Shares: +2,012,035
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 2,500,000 | 147,100 | $39,999,780 | $2,755,758 | +$37,244,022 |
| 3-6 | 0 | 166,100 | $0 | $3,097,878 | -$3,097,878 |
| 6-9 | 0 | 158,936 | $0 | $2,668,400 | -$2,668,400 |
| 9-12 | 0 | 15,829 | $0 | $165,096 | -$165,096 |
Bicara Therapeutics Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director, 10%+ Owner | $108,854,468 | +$39,999,780 | +58% | Filing P/S | 26 Feb 2026 |
| Kiran Mazumdar-Shaw | Director, 10%+ Owner | $83,184,246 | Mixed | 09 Jun 2025 | ||
| Biocon Ltd | 10%+ Owner | $73,155,178 | Mixed | 16 Sep 2024 | ||
| TPG GP A, LLC | Former 10% Owner | $25,962,692 | Mixed | 16 Sep 2024 | ||
| James E. Flynn | Possible Members of 10% Group, 10%+ Owner | $23,774,208 | Mixed | 17 Sep 2024 | ||
| FMR LLC | Other* | $14,770,801 | Mixed | 16 Sep 2024 | ||
| FIL Ltd | Other* | $13,426,861 | Mixed | 16 Sep 2024 | ||
| Claire Mazumdar | Chief Executive Officer, Director | $6,431,919 | -$2,838,473 | -31% | Filing P/S | 18 Mar 2026 |
| Ryan Cohlhepp | President and COO, Director | $3,944,020 | -$2,297,008 | -37% | Filing P/S | 16 Mar 2026 |
| Ivan Hyep | Chief Financial Officer | $2,691,407 | -$1,685,178 | -39% | Filing P/S | 23 Mar 2026 |
| David Raben | Chief Medical Officer | $1,047,713 | -$1,020,848 | -49% | Filing P/S | 25 Mar 2026 |
| Nils Lonberg | Director | $397,183 | Mixed | 09 Jun 2025 | ||
| Kate Haviland | Director | $98,491 | Mixed | 09 Jun 2025 | ||
| Lara Meisner | Chief Legal Officer | $0 | -$845,625 | -100% | Mixed | 02 Feb 2026 |
| Jake Simson | Director | Mixed | 09 Jun 2025 | |||
| Michael Powell | Director | Mixed | 09 Jun 2025 | |||
| Christopher Bowden | Director | Mixed | 09 Jun 2025 | |||
| Carolyn Ng | Director | Mixed | 12 Sep 2024 | |||
| Scott M. Robertson | Director | Mixed | 09 Jun 2025 |
Top shareholders of Bicara Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
|
Company |
10%
|
6,605,780
|
$131,386,982 | +$67,012,079 | 31 Mar 2026 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
3/4/5
13F
|
Director, 10%+ Owner · Company |
12%
|
7,279,739
|
$123,100,386 | $0 | 26 Feb 2026 | |
| Siren, L.L.C. |
13F
|
Individual |
8%
|
5,216,969
|
$87,801,588 | — | 31 Dec 2025 | |
| Kiran Mazumdar-Shaw |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
6,304,931
mixed-class rows
|
$83,184,246 | — | 09 Jun 2025 | |
| Biocon Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,523,897
|
$73,155,178 | — | 16 Sep 2024 | |
| Vestal Point Capital, LP |
13D/G
13F
|
Company |
6.5%
|
3,575,000
|
$62,669,750 | -$24,980,250 | 31 Dec 2025 | |
| FMR LLC |
13D/G
3/4/5
13F
|
Other* · Company |
6.1%
|
3,347,223
|
$56,333,763 | +$9,946,631 | 31 Dec 2025 | |
| Red Tree Management, LLC |
13F
|
Company |
4.8%
|
3,170,509
|
$53,359,666 | — | 31 Dec 2025 | |
| TPG GP A, LLC |
13F
3/4/5
|
Company · Former 10% Owner |
4.6%
|
3,010,425
|
$50,665,453 | — | 31 Dec 2025 | |
| Invus Global Management, LLC |
13D/G
|
Raymond Debbane |
9.6%
|
5,216,969
|
$50,656,769 | $0 | 30 Jun 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
5%
|
2,750,000
|
$48,207,500 | $0 | 05 Feb 2026 | |
| Royalty Pharma Sub-Manager, LLC |
13F
|
Company |
1.9%
|
1,263,150
|
$45,864,977 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
4%
|
2,646,285
|
$44,484,051 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
3.9%
|
2,528,451
|
$42,553,826 | — | 31 Dec 2025 | |
| Omega Fund Management, LLC |
13F
|
Company |
3.4%
|
2,204,650
|
$37,104,260 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.3%
|
2,186,150
|
$36,792,904 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
1,649,537
|
$27,761,708 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.5%
|
1,620,025
|
$27,265,020 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.4%
|
1,559,535
|
$26,248,000 | — | 31 Dec 2025 | |
| James E. Flynn |
3/4/5
|
Possible Members of 10% Group, 10%+ Owner |
—
class O/S missing
|
1,795,174
|
$23,774,208 | — | 17 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
811,400
|
$13,658,764 | — | 31 Dec 2025 | |
| FIL Ltd |
3/4/5
13F
|
Other* · Company |
1.2%
from 13F
|
1,013,853
|
$13,426,861 | — | 16 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.2%
|
772,258
|
$12,997,102 | — | 31 Dec 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
0.98%
|
643,382
|
$10,828,113 | — | 31 Dec 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
0.87%
|
568,919
|
$9,574,907 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.84%
|
552,331
|
$9,295,731 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.66%
|
434,699
|
$7,315,984 | — | 31 Dec 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.66%
|
429,095
|
$7,221,669 | — | 31 Dec 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.61%
|
401,444
|
$6,756,303 | — | 31 Dec 2025 | |
| Claire Mazumdar |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
515,499
mixed-class rows
|
$6,431,919 | -$2,838,473 | 18 Mar 2026 | |
| NAN FUNG TRINITY (HK) Ltd |
13F
|
Company |
0.57%
|
372,385
|
$6,267,240 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.51%
|
335,682
|
$5,649,529 | — | 31 Dec 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.49%
|
318,269
|
$5,356,000 | — | 31 Dec 2025 | |
| Clearbridge Investments, LLC |
13F
|
Company |
0.46%
|
298,762
|
$5,028,161 | — | 31 Dec 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.46%
|
298,575
|
$5,025,017 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.42%
|
272,145
|
$4,580,200 | — | 31 Dec 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.4%
|
261,583
|
$4,402,442 | — | 31 Dec 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.37%
|
244,626
|
$4,117,056 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.36%
|
237,107
|
$3,990,511 | — | 31 Dec 2025 | |
| Ryan Cohlhepp |
3/4/5
|
President and COO, Director |
—
mixed-class rows
|
317,975
mixed-class rows
|
$3,944,020 | -$2,297,008 | 16 Mar 2026 | |
| Woodline Partners LP |
13F
|
Company |
0.36%
|
232,690
|
$3,916,173 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.32%
|
209,100
|
$3,519,153 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.29%
|
192,191
|
$3,234,575 | — | 31 Dec 2025 | |
| Ivan Hyep |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
194,299
mixed-class rows
|
$2,691,407 | -$1,685,178 | 23 Mar 2026 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.23%
|
150,000
|
$2,524,500 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.21%
|
136,522
|
$2,297,665 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.2%
|
128,626
|
$2,164,776 | — | 31 Dec 2025 | |
| Napean Trading & Investment Co (Singapore) PTE Ltd |
13F
|
Company |
0.17%
|
113,780
|
$1,914,917 | — | 31 Dec 2025 | |
| Atle Fund Management AB |
13F
|
Company |
0.17%
|
111,363
|
$1,874,239 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.17%
|
109,456
|
$1,842,146 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Bicara Therapeutics Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Raben | BCAX | Common Stock | Sale | -9.05% | $104,229 | $18.95 | -5,500 | 55,286 | 25 Mar 2026 | Direct |
| David Raben | BCAX | Common Stock | Options Exercise | 9.95% | 5,500 | 60,786 | 25 Mar 2026 | Direct | ||
| David Raben | BCAX | Stock Option (Right to Buy) | Options Exercise | -10.4% | -5,500 | 47,413 | 25 Mar 2026 | Direct | ||
| Ivan Hyep | BCAX | Common Stock | Sale | -5.95% | $170,348 | $18.52 | -9,200 | 145,355 | 23 Mar 2026 | Direct |
| Ivan Hyep | BCAX | Common Stock | Options Exercise | 6.33% | 9,200 | 154,555 | 23 Mar 2026 | Direct | ||
| Ivan Hyep | BCAX | Stock Option (Right to Buy) | Options Exercise | -15.8% | -9,200 | 48,944 | 23 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -0.47% | $30,246 | $18.95 | -1,596 | 339,392 | 20 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 0.47% | 1,596 | 340,988 | 20 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -0.9% | -1,596 | 176,107 | 20 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -1.99% | $129,705 | $18.78 | -6,905 | 339,392 | 19 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 2.03% | 6,905 | 346,297 | 19 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -3.74% | -6,905 | 177,703 | 19 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -1.88% | $122,415 | $18.84 | -6,499 | 339,392 | 18 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 1.91% | 6,499 | 345,891 | 18 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -3.4% | -6,499 | 184,608 | 18 Mar 2026 | Direct | ||
| Ryan Cohlhepp | BCAX | Common Stock | Sale | -5.86% | $245,714 | $19.66 | -12,500 | 200,641 | 16 Mar 2026 | Direct |
| Ryan Cohlhepp | BCAX | Common Stock | Options Exercise | 3.9% | 8,000 | 213,141 | 16 Mar 2026 | Direct | ||
| Ryan Cohlhepp | BCAX | Stock Option (Right to Buy) | Options Exercise | -6.38% | -8,000 | 117,334 | 16 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -9.77% | $704,657 | $19.17 | -36,766 | 339,392 | 09 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 10.8% | 36,766 | 376,158 | 09 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -16.1% | -36,766 | 191,107 | 09 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -1.11% | $71,572 | $18.75 | -3,817 | 339,392 | 06 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 1.12% | 3,817 | 343,209 | 06 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -1.65% | -3,817 | 227,873 | 06 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -0.52% | $33,464 | $18.74 | -1,786 | 339,392 | 05 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 0.53% | 1,786 | 341,178 | 05 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -0.76% | -1,786 | 231,690 | 05 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Common Stock | Sale | -0.77% | $49,289 | $18.73 | -2,631 | 339,392 | 04 Mar 2026 | Direct |
| Claire Mazumdar | BCAX | Common Stock | Options Exercise | 0.78% | 2,631 | 342,023 | 04 Mar 2026 | Direct | ||
| Claire Mazumdar | BCAX | Stock Option (Right to Buy) | Options Exercise | -1.11% | -2,631 | 233,476 | 04 Mar 2026 | Direct | ||
| Ivan Hyep | BCAX | Common Stock | Sale | -2% | $54,062 | $18.25 | -2,963 | 145,355 | 04 Mar 2026 | Direct |
| Ivan Hyep | BCAX | Common Stock | Options Exercise | 2.04% | 2,963 | 148,318 | 04 Mar 2026 | Direct | ||
| Ivan Hyep | BCAX | Stock Option (Right to Buy) | Options Exercise | -3.58% | -2,963 | 79,784 | 04 Mar 2026 | Direct | ||
| David Raben | BCAX | Common Stock | Sale | -22.8% | $301,920 | $18.52 | -16,300 | 55,286 | 04 Mar 2026 | Direct |
| David Raben | BCAX | Common Stock | Options Exercise | 29.5% | 16,300 | 71,586 | 04 Mar 2026 | Direct | ||
| David Raben | BCAX | Stock Option (Right to Buy) | Options Exercise | -23.6% | -16,300 | 52,913 | 04 Mar 2026 | Direct | ||
| Ryan Cohlhepp | BCAX | Common Stock | Sale | -7.82% | $315,893 | $18.16 | -17,392 | 205,141 | 03 Mar 2026 | Direct |
| Ryan Cohlhepp | BCAX | Common Stock | Options Exercise | 6.15% | 12,892 | 222,533 | 03 Mar 2026 | Direct | ||
| Ryan Cohlhepp | BCAX | Stock Option (Right to Buy) | Options Exercise | -9.33% | -12,892 | 125,334 | 03 Mar 2026 | Direct | ||
| Ivan Hyep | BCAX | Common Stock | Sale | -8.53% | $246,910 | $18.22 | -13,555 | 145,355 | 03 Mar 2026 | Direct |
| Ivan Hyep | BCAX | Common Stock | Options Exercise | 9.33% | 13,555 | 158,910 | 03 Mar 2026 | Direct | ||
| Ivan Hyep | BCAX | Stock Option (Right to Buy) | Options Exercise | -18.9% | -13,555 | 58,144 | 03 Mar 2026 | Direct | ||
| David Raben | BCAX | Common Stock | Sale | -0.36% | $3,690 | $18.45 | -200 | 55,286 | 03 Mar 2026 | Direct |
| David Raben | BCAX | Common Stock | Options Exercise | 0.36% | 200 | 55,486 | 03 Mar 2026 | Direct | ||
| David Raben | BCAX | Stock Option (Right to Buy) | Options Exercise | -0.29% | -200 | 69,213 | 03 Mar 2026 | Direct | ||
| Ra Capital Management, L.P. | BCAX | Common Stock | Purchase | 6.97% | $4,800,000 | $16.00 | 300,000 | 4,603,418 | 26 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | BCAX | Pre-Funded Warrant (Right to Buy) | Purchase | $35,199,780 | $16.00 | 2,200,000 | 2,200,000 | 26 Feb 2026 | See Footnotes | |
| Ryan Cohlhepp | BCAX | Common Stock | Sale | -1.7% | $65,501 | $18.04 | -3,631 | 209,641 | 25 Feb 2026 | Direct |
| Ryan Cohlhepp | BCAX | Common Stock | Options Exercise | 1.48% | 3,108 | 213,272 | 25 Feb 2026 | Direct | ||
| Ryan Cohlhepp | BCAX | Stock Option (Right to Buy) | Options Exercise | -2.2% | -3,108 | 138,226 | 25 Feb 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.